Benefits
Generalized anxiety disorder vs medazepam (Zozulia 2008 pivotal)
Zozulia 2008 (PMID 18454096, Zh Nevrol Psikhiatr Im S S Korsakova 108(4):38-48) — 62 patients with GAD and neurasthenia compared selank (n=30) vs medazepam (n=32, benzodiazepine). Anxiolytic effects on Hamilton/Zung/CGI scales were SIMILAR for both drugs, but selank ADDITIONALLY showed antiasthenic and psychostimulant effects without medazepam's sedation. Foundational positive RCT supporting Russian approval. Limited by Russian-language literature less accessible to Western reviews.
Anxiety vs phenazepam (Medvedev 2014)
Medvedev 2014 (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 114(7):17-22) compared selank vs phenazepam (Russian benzodiazepine) for anxiety disorders. Selank produced significant improvement in QUALITY OF LIFE without noticeable side effects vs phenazepam. Establishes selank as benzodiazepine-comparable anxiolytic with superior tolerability profile.
Rapid responder identification (Sluchevskaya 2012)
ScienceDirect P-1114 study evaluated rapid vs delayed treatment response in 20 GAD patients (DSM-IV) given selank 2700 μg/day intranasally. 40% identified as RAPID RESPONDERS with abrupt symptom reduction in days 1-3. Day 3 HAM-A reduced from 20.3±11.9 to 7.0±2.9 (p<0.01) in rapid responders. Rapid responders had more asthenic and cognitive symptoms with higher EEG-reactivity than complete responders. Important treatment response heterogeneity finding.
GABA-A allosteric modulation (Kasian 2017 mechanism)
Kasian 2017 (Behav Neurol 2017:5091027, PMC5322660) demonstrated selank administration alters expression of 45 genes involved in GABAergic neurotransmission in rat frontal cortex within 1 hour. Pattern shows positive correlation with GABA itself, indicating selank functions as ALLOSTERIC GABA-A MODULATOR rather than direct agonist. This allosteric mechanism may explain absence of dependence/withdrawal seen with benzodiazepines (which are direct GABA-A modulators with different binding profile).
Enkephalin stabilization (anxiolytic mechanism)
Zozulya 2001 (PMID 11550013, Bull Exp Biol Med 131(4):315-317) showed selank inhibits enkephalin-degrading enzymes — extending duration of endogenous opioid anxiolytic peptides. Mechanism for proposed mood-modulating effects via endogenous opioid system support. Distinct from benzodiazepine mechanism.
Anti-inflammatory effects (clinical observations)
Selank has demonstrated potential to reduce inflammation by inhibiting IL-6 gene activity. Useful for anxiety disorders with comorbid inflammatory features (chronic fatigue, fibromyalgia-like symptoms). Limited rigorous trials but consistent clinical observations across Russian use.
Mechanism of action
Allosteric GABA-A receptor modulation (NOT direct agonist)
Selank functions as ALLOSTERIC GABA-A modulator — alters receptor activity through non-active site binding. Distinguishes from benzodiazepines (which are direct GABA-A modulators at the benzodiazepine binding site). Allosteric mechanism may explain absence of dependence, tolerance, sedation, and withdrawal — major advantages over benzodiazepines clinically.
Enkephalin-degrading enzyme inhibition
Inhibits enzymes that break down enkephalin endogenous opioid peptides. Extending enkephalin duration provides anxiolytic and mood-stabilizing effects via endogenous opioid system. Mechanism distinct from exogenous opioid agonists — modulates endogenous tone.
Serotonin metabolism modulation
Animal studies suggest selank affects serotonin metabolism in CNS. Mechanism for proposed mood effects beyond pure GABA modulation. Less clinically validated than GABA-A and enkephalin mechanisms.
Tuftsin-derived immunomodulation
Selank contains tuftsin tetrapeptide N-terminus (Thr-Lys-Pro-Arg) — endogenous immunomodulatory peptide. Inherits some tuftsin properties: phagocyte activation, immune modulation. Mechanism for anti-inflammatory effects observed clinically.
BDNF and gene expression effects
Modulates expression of multiple genes involved in BDNF pathway, glucocorticoid receptors, and stress response. Mechanism for sustained anxiolytic effects beyond acute receptor modulation.
Intranasal BBB penetration
Intranasal administration provides direct CNS access via olfactory and trigeminal nerves — bypassing first-pass hepatic metabolism. Practical advantage of peptide compounds; rapid onset 30-60 minutes.
Clinical trials
Russian-language clinical trial (Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB 2008, Zh Nevrol Psikhiatr Im S S Korsakova 108(4):38-48, PMID 18454096).
62 patients with generalized anxiety disorder (GAD) and neurasthenia. Selank (n=30) vs medazepam (n=32, benzodiazepine). Hamilton, Zung, CGI psychometric scales. Enkephalin activity in blood serum measured.
Anxiolytic effects of selank and medazepam SIMILAR. Selank ADDITIONALLY showed ANTIASTHENIC and PSYCHOSTIMULANT effects without medazepam's sedation. Clinical-biological study: GAD/neurasthenia patients had decreased τ½ leu-enkephalin correlated with disease duration, anxiety severity, asthenia, autonomic disorders. Selank treatment INCREASED this parameter with stronger positive correlations with anxiety level. Russian-language literature limits Western methodological scrutiny.
Mechanistic study (Zozulya AA, Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LN, Zolotarev YA, Ivanov SV, Andryushchenko AV, Myasoedov NF, Smulevich AB 2001, Bull Exp Biol Med 131(4):315-317, doi:10.1023/a:1017979514274, PMID 11550013).
Biochemical study of selank effects on enkephalin-degrading enzymes in serum/tissue.
Selank INHIBITS ENKEPHALIN-DEGRADING ENZYMES — extending duration of endogenous opioid anxiolytic peptides. Foundational mechanism evidence for selank's anxiolytic activity via endogenous opioid system support. Distinct mechanism from benzodiazepine GABA modulation.
Behavioral and gene expression study (Kasian A, Kolomin T, Yatskou M, Myasoedov N, Slominsky P, Shadrina M 2017, Behav Neurol 2017:5091027, doi:10.1155/2017/5091027). PMC5322660.
Rats in unpredictable chronic mild stress paradigm receiving selank ± diazepam. Frontal cortex transcriptome (45 GABAergic genes) analyzed within 1 hour post-administration.
Selank ALTERED EXPRESSION of 45 GABAergic genes within 1 hour. Pattern showed POSITIVE CORRELATION with GABA itself — indicating selank functions as ALLOSTERIC GABA-A MODULATOR rather than direct agonist. Selank ENHANCED diazepam's anxiolytic effect in stress model (synergistic). Foundational mechanistic evidence supporting safety profile (no dependence/withdrawal) vs benzodiazepines.
About this ingredient
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TP-7) is a SYNTHETIC HEPTAPEPTIDE developed at the Institute of Molecular Genetics of the RUSSIAN ACADEMY OF SCIENCES. Designed by combining the endogenous TUFTSIN (Thr-Lys-Pro-Arg) immunomodulatory tetrapeptide with a stabilizing Pro-Gly-Pro (PGP) C-terminus tripeptide for peptidase resistance. PRIMARY PHARMACOLOGY: ALLOSTERIC GABA-A RECEPTOR MODULATOR (distinct from benzodiazepines which bind benzodiazepine site directly), enkephalin-degrading enzyme INHIBITOR (extending endogenous opioid anxiolytic effects), serotonin metabolism modulator, immunomodulator (via tuftsin properties).
REGULATORY STATUS: Approved in RUSSIA as nasal spray for: generalized anxiety disorder (GAD), neurasthenia, asthenia, anxiety with autonomic symptoms, post-stress recovery. NOT FDA-approved; sold as 'research peptide' in US (gray zone). Available as lyophilized powder for reconstitution; intranasal administration standard.
KEY ADVANTAGE over benzodiazepines: NO sedation, NO cognitive impairment, NO tolerance, NO dependence, NO withdrawal — addressing major limitations of conventional anxiolytics. Mechanism via allosteric (vs direct) GABA-A modulation hypothesized to explain favorable safety profile. CLINICAL EVIDENCE BASE: ZOZULIA 2008 PMID 18454096 PIVOTAL RCT (n=62) showing selank anxiolytic equivalence to medazepam (benzodiazepine) with additional antiasthenic and psychostimulant benefits; ZOZULYA 2001 PMID 11550013 enkephalin-degrading enzyme inhibition foundational mechanism; KASIAN 2017 PMC5322660 GABA-A allosteric mechanism evidence with diazepam synergy; MEDVEDEV 2014 Russian study comparing favorably to phenazepam (Russian benzodiazepine); SLUCHEVSKAYA 2012 rapid responder identification.
Russian-language literature predominantly — significant publication accessibility limitations for Western systematic reviews. EVIDENCE: 2/5 reflects: (1) Zozulia 2008 PIVOTAL RCT vs medazepam, (2) Russian regulatory approval based on multiple clinical trials, (3) Kasian 2017 rigorous mechanism evidence in rats, (4) Medvedev 2014 confirmation vs phenazepam, (5) Russian-language literature limitations on Western evidence assessment, (6) gray US regulatory status, (7) intranasal peptide formulation challenges (research-grade product quality variable). SAFETY: Excellent — major advantage over benzodiazepines.
Best positioned as: (a) GAD/neurasthenia adjunct in Russia under prescription with established efficacy/safety profile, (b) ANXIOLYTIC ALTERNATIVE for those wanting to avoid benzodiazepine dependence/withdrawal/cognitive effects, (c) STRESS/ASTHENIA adjunct (broader Russian indication), (d) NOOTROPIC adjunct for anxiety-related cognitive impairment, (e) NOT FDA-approved — research peptide status in US warrants regulatory caution, (f) intranasal route may be impractical for some users vs oral medications, (g) Russian-only published evidence limits Western clinical translation. Honest framing: selank is the most promising of the Russian peptide anxiolytics — pivotal Zozulia 2008 RCT showing benzodiazepine-equivalent anxiolytic efficacy WITHOUT dependence/withdrawal would be clinically significant if confirmed in Western RCT framework. Russian regulatory approval reflects accumulated clinical evidence.
Allosteric GABA mechanism is biochemically interesting and supports favorable safety profile. Reasonable for anxiety treatment in Russia under medical supervision; research/gray-zone status in US warrants caution. Western RCT replication would be valuable for broader clinical adoption.